Icon Genetics GmbH (ICON), Munich/Halle, Germany, a plant biotechnology company, has announced that the Company has been awarded a prestigious Frost & Sullivan European Technology Innovation Award.
For the Technology Innovation Award, the following criteria were used to benchmark Icon Genetics’ performance against key competitors: uniqueness of the technology; impact on new products/applications; impact on functionality; impact on customer value, and relevance of the innovation to the industry. To support its evaluation of best practices across multiple business performance categories, Frost & Sullivan employs a customized Decision Support Matrix (DSM), an analytical tool that compares companies’ performance relative to each other with an integration of quantitative and qualitative metrics. The DSM follows a 10-point scale that allows for nuances in performance evaluation. The analysts of Frost & Sullivan have rated Icon Genetics’ technology as ‘excellent’ and ‘the best in its class’ with an overall rating of 9.3.
The report concludes: ”Icon Genetics has established itself as a leader in the development of a suite of tools for plant-based recombinant expression. They have conducted systematic studies of all routes for expressing recombinant proteins in plants and they have developed optimized tool sets for each route. Their business model is customer-centric as they do not merely have a licensing proposition, but also train their customers to use their magnICON® and other systems in a joint effort of research and development. They also have their own cGMP-compliant facility, enabling them to develop and manufacture in-house products. The efficiency and yield of recombinant protein from plants is the highest in the industry and they have expanded their application endeavors to include non-pharmaceutical uses of recombinant proteins in antimicrobials and antivirals through Nomad Biosciences, its parent company. Based on Frost & Sullivan’s independent analysis of Recombinant Expression Systems, Icon Genetics is recognized with the 2012 European Technology Innovation Award.”
Icon Genetics is currently a wholly owned subsidiary of Nomad Bioscience GmbH, Munich, Germany. The Company discovers and develops new biopharmaceuticals and high-value protein products using green plants as production hosts. ICON offers new plant manufacturing technologies which address speed, yield, precision, expression control and safety of product manufacturing in plants. ICON operates its own cGMP-compliant manufacturing facility in Halle, Germany. ICON’s own pipeline includes several ‘biobetter’ anti-cancer antibodies (pre-clinical stage).
About Frost & Sullivan:
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1,000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To learn more, please visit http://www.frost.com.